Evidence map›Paper›PMID 40746536›Full record

ReviewFrontiers in immunology2025

Research progress of PYK2 in digestive system diseases.

Yiyao Duan, Mingzhu Xie, Hui Wang, Sijing Chen, Jun Hu, Xujia Chen, Hong Ping Jia, Ningyan Zhang, Ling Peng, Xiang Li and 3 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yiyao DuanDepartment of Gastroenterology, Yan' an Hospital Affiliated to Kunming Medical University, Kunming, Yunnan, China.
Mingzhu XieDepartment of Gynecology, Kunming Maternity and Child Care Hospital, Kunming, Yunnan, China.
Hui WangDepartment of Gastroenterology, Yan' an Hospital Affiliated to Kunming Medical University, Kunming, Yunnan, China.
Sijing ChenDepartment of Gastroenterology, Yan' an Hospital Affiliated to Kunming Medical University, Kunming, Yunnan, China.
Jun HuDepartment of Orthopedics, The First People's Hospital of Kunming, Kunming, Yunnan, China.
Xujia ChenDepartment of Gastroenterology, Yan' an Hospital Affiliated to Kunming Medical University, Kunming, Yunnan, China.
Hong Ping JiaDepartment of Gastroenterology, Yan' an Hospital Affiliated to Kunming Medical University, Kunming, Yunnan, China.
Ningyan ZhangDepartment of Gastroenterology, Yan' an Hospital Affiliated to Kunming Medical University, Kunming, Yunnan, China.
Ling PengDepartment of Gastroenterology, Yan' an Hospital Affiliated to Kunming Medical University, Kunming, Yunnan, China.
Xiang LiCollege of Basic Medical Sciences, Kunming Medical University, Kunming, Yunnan, China.
Hameed Ullah KhanDepartment of Gastroenterology, Yan' an Hospital Affiliated to Kunming Medical University, Kunming, Yunnan, China.
Die HuClinical Medical College, Hunan University of Medicine, Huaihua, Hunan, China.
Rong QinDepartment of Gastroenterology, Yan' an Hospital Affiliated to Kunming Medical University, Kunming, Yunnan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Belonging to the focal adhesion kinase (FAK) family, proline-rich tyrosine kinase 2 (PYK2) is a non-receptor tyrosine kinase, has become a focal point in cancer research owing to its essential participation in the formation and dissemination of tumors. Studies have shown that this kinase controls various cellular activities, including: tumor cell adhesion, growth, multiplication, specialization, and detachment, making it a promising target for developing anticancer drugs. The goal of this review is to analyze the multifaceted role of PYK2 in gastrointestinal disease, focusing on its contribution to tumor progression, associated signaling pathways, and the therapeutic potential of PYK2 inhibitors in improving disease management and prognosis.

Indexed as

Digestive System DiseasesFocal Adhesion Kinase 2AnimalsFocal Adhesion Kinase 1HumansProtein Kinase InhibitorsSignal TransductionFocal Adhesion Kinase 1Focal Adhesion Kinase 2Protein Kinase InhibitorsPTK2 protein, humandigestive system diseasesPYK2signaling pathwaystargeted therapytumor progression

Identifiers

PMID40746536
PMCPMC12310472

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.